Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
-
New research suggests amyloid β and BACE1 may protect the brain by binding toxic metals, rather than causing Alzheimer’s.
-
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
-
NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
-
NeuroAge Therapeutics launches the NeuroAge Test, a cutting-edge tool predicting dementia risk 30 years early to optimize brain health
-
Allyx Therapeutics has been awarded a $3.3 million grant as part of the NIH's Small Business Innovation Research Commercial Readiness Pilot program
-
NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
-
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative...
-
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
-
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer